Biodexa Sets 1-for-8 ADS Reverse Split Effective October 26
Summary
Biodexa announced a 1-for-8 reverse ADS split effective October 26, 2026, changing the ADS ratio from 1:50 to 1:400 ordinary shares. ADS holders must exchange 8 old ADSs for 1 new ADS.
Key Events · Corporate Governance and Compliance · BDRX
-
1-for-8 Reverse ADS Split Announced
Biodexa is changing its ADS ratio from 1 ADS per 50 ordinary shares to 1 ADS per 400 ordinary shares, equivalent to a 1-for-8 reverse ADS split.
-
Effective Date October 26, 2026
The Ratio Change is expected to take effect on or about October 26, 2026, with mandatory exchange of 8 old ADSs for 1 new ADS.
-
New CUSIP Assigned
New ADSs will trade under CUSIP 59564R864, replacing old CUSIP 59564R872.
-
Follows Prior Reverse Split Approval
This follows the shareholder-approved 1-for-10,000 reverse stock split on July 29, 2026, and comes amid a going concern warning with £3.23 million cash as of June 30, 2026.
Analysis · BDRX · Life Sciences
Biodexa is changing its ADS ratio from 1 ADS per 50 ordinary shares to 1 ADS per 400 ordinary shares, which has the same effect as a 1-for-8 reverse ADS split. ADS holders must surrender their old ADSs to receive one new ADS for every eight old ADSs, with no fractional ADSs allocated. The effective date is expected on or about October 26, 2026. This follows the shareholder-approved 1-for-10,000 reverse stock split on July 29, 2026, and comes amid a going concern warning and a cash balance of only £3.23 million as of June 30, 2026. The reverse split is a compliance measure to maintain NASDAQ listing requirements, but it does not change the underlying ordinary shares or the company's fundamental financial position.
How filings like this one have moved
In the 30 days to Oct 31, 2026, 31.7% of the 1731 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BDRX was trading at $0.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $360.4K. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.